Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.

@article{Nanda2016PembrolizumabIP,
  title={Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.},
  author={Rita Nanda and Laura Quan Man Chow and Elizabeth Claire Dees and Raanan Berger and Sudeep Gupta and Ravit Geva and Lajos Pusztai and Kumudu Pathiraja and Gursel Aktan and Jonathan D. Cheng and Vassiliki Karantza and Laurence Buisseret},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2016},
  volume={34 21},
  pages={
          2460-7
        }
}
PURPOSE Immune checkpoint inhibition has been demonstrated to be an effective anticancer strategy. Several lines of evidence support the study of immunotherapy in triple-negative breast cancer (TNBC). We assessed the safety and antitumor activity of the programmed cell death protein 1 (PD-1) inhibitor pembrolizumab in patients with advanced TNBC. METHODS KEYNOTE-012 (ClinicalTrials.gov identifier: NCT01848834) was a multicenter, nonrandomized phase Ib trial of single-agent pembrolizumab given… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 257 CITATIONS, ESTIMATED 41% COVERAGE

Immune Checkpoint Inhibitor Therapy in Breast Cancer.

  • Journal of the National Comprehensive Cancer Network : JNCCN
  • 2018
VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

The clinical promise of immunotherapy in triple-negative breast cancer

  • Cancer management and research
  • 2018
VIEW 11 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Immune Checkpoint Blockade in Breast Cancer Therapy.

  • Advances in experimental medicine and biology
  • 2017
VIEW 10 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Early Phase Cancer Immunotherapy

  • Current Cancer Research
  • 2018
VIEW 12 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2015
2019

CITATION STATISTICS

  • 17 Highly Influenced Citations

  • Averaged 76 Citations per year over the last 3 years

References

Publications referenced by this paper.
SHOWING 1-10 OF 42 REFERENCES

Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2008
VIEW 7 EXCERPTS
HIGHLY INFLUENTIAL

Pembrolizumab for the treatment of non-small cell lung cancer.

  • Expert opinion on biological therapy
  • 2016
VIEW 2 EXCERPTS

In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2014

Similar Papers

Loading similar papers…